Jeanne Demoss
Cardiovascular Disease · East Brunswick, NJNPI 1245263144
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novartis at 45.5% of the total. Reporting peaked in 2019 at $437 and has fallen 83.6% since, to $72 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 178 payments — averaging $6.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$506
- Johnson & Johnson$193
- Kowa Pharmaceuticals America, Inc.$180
- Amgen$44
- E.r. Squibb & Sons, L.L.C.$30
- Abiomed$29
- plus $130 from 7 others
What the payments were for
- Food & beverage$1,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 107 | $506 |
| Johnson & Johnson | 21 | $193 |
| Kowa Pharmaceuticals America, Inc. | 35 | $180 |
| Amgen | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Abiomed | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Gilead | 2 | $26 |
| Boston Scientific | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Merck | 1 | $13 |
How this compares
$1,112 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $27,801 |
| Atorvastatin Calcium | 26 | $247 |
| Amlodipine Besylate | 28 | $238 |
| Rosuvastatin Calcium | 19 | $234 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in East Brunswick
- Anthony AltobelliEast Brunswick$137K
- David SchaerEast Brunswick$75K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.